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Abstract
Objective
The objective of this study was to assess the cost-effectiveness of induction and mainte-
nance treatment up to 1 year of ulcerative colitis with golimumab/standard care and stan-
dard care alone in Poland.
Methods
AMarkov model was used to estimate the expected costs and effects of golimumab/stan-
dard care and a standard care alone. For each treatment option the costs and quality
adjusted life years were calculated to estimate the incremental cost-utility ratio. The analysis
was performed from the perspective of the Polish public payer and society over a 30-years
time horizon. The clinical parameters were derived mainly from the PURSUIT-SC and PUR-
SUIT-M clinical trials. Different direct and indirect costs and utility values were assigned to
the various model health states.
Results
The treatment of ulcerative colitis patients with golimumab/standard care instead of a stan-
dard care alone resulted in 0.122 additional years of life with full health. The treatment with
golimumab/standard care was found to be more expensive than treatment with the standard
care alone from the public payer perspective and from social perspective. The incremental
cost-utility ratio of golimumab/standard care compared to the standard care alone is esti-
mated to be 391,252 PLN/QALY gained (93,155 €/QALYG) from public payer perspective
and 374,377 PLN/QALY gained (89,137 €/QALYG) from social perspective.
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Conclusions
The biologic treatment of ulcerative colitis patients with golimumab/standard care is more
effective but also more costly compared with standard care alone.
Introduction
Ulcerative colitis (UC) is an idiopathic inflammatory bowel disorder characterized by an
inflammatory reaction involving the colonic mucosa [1,2]. The clinical course is unpredictable
and marked by alternating periods of exacerbation and remission, which may occur spontane-
ously or in response to environmental, psychosocial or treatment changes or intercurrent ill-
nesses, as well as other medical factors influencing disease status [3,4]. Although progress has
been made in the overall management of the disease, no medical cure has been discovered [5].
The therapy of ulcerative colitis is directed at quickly resolving symptoms and subsequently
maintaining symptom-free periods. Lifelong medical treatment is required, and sometimes,
when there is no alternative treatment option and the disease is very severe, the surgery is per-
formed. Conventional therapy comprises corticosteroids, aminosalicylates and drugs that affect
the immune response. Ulcerative colitis has a significant impact on quality of life and daily
activity, as patients experience loss of energy, negative self-image, social fear [4].
Until recently, surgery was the only remaining choice for severe chronic ulcerative colitis
patients who failed standard treatment (i.e. cyclosporine, corticosteroids, 6-mercaptopurine, aza-
thioprine), or when it was not tolerated. In rare cases, non-traditional therapies such as tacrolimus,
and thalidomide have been used with varying degrees of success. The introduction of anti-tumor
necrosis factor-alfa (anti-TNFα) treatment allowed a new option for the management of ulcerative
colitis and is expected to decrease the rate of colectomies or at least to extend the time to surgery,
compared with standard treatment. TNFα is a proinflammatory cytokine found at increased con-
centrations in the blood, colonic tissue and stools of ulcerative colitis patients [2]. Golimumab is a
human monoclonal antibody which prevents the binding of TNFα to its receptors [6]. On the one
hand clinical trials suggest that golimumab/standard care has superior efficacy compared to stan-
dard care alone in moderate to severe non-acute UC [7,8]. On the other hand, the use of biologics
constitutes a heavy burden for the public payer, so its usage can be limited in many countries.
In Poland, patients with severe UC who are not able to have ciclosporine therapy and don't
respond to standard care have the possibility to receive the induction treatment with inflixi-
mab, which consists of 3 administrations of the drug. At present, there is no biological mainte-
nance treatment of ulcerative colitis reimbursed in Poland, hence patients often lose their
response or remission, which were achieved during the induction phase. Additionally, the lack
of biological maintenance treatment leads to an increased rate of colectomies. In this connec-
tion, there was a need for economic evaluation of UC induction and maintenance therapy with
a TNFα inhibitor at Polish settings.
This study uses an economic evaluation to assess the cost-effectiveness of induction and
maintenance treatment up to 1 year of ulcerative colitis with golimumab/standard care and
standard care alone in Poland.
Materials and Methods
Overview
AMarkov model was used to estimate the expected costs and effects of golimumab/standard
care and standard care alone used in the induction and maintenance treatment of moderate to
severe ulcerative colitis (model structure, inputs, transition probabilities, costs of health states,
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and utilities are presented in Fig 1, Tables 1 and 2). The analysis was taken from the perspective
of the Polish public payer (National Health Fund, NHF) and also from social perspective (indi-
rect costs included). Ulcerative colitis could be a lifelong disease, which is why the thirty-years’
time horizon was selected for the base-case analysis. Costs and outcomes were discounted at an
annual rate of 5% and 3.5%, respectively.
The target population consists of a hypothetical cohort of patients with an established diag-
nosis of UC and moderate to severe disease activity, defined as a Mayo score of 6–12, with an
endoscopic subscore> 2 [7,8]. The cyclosporine therapy should be contraindicated or not tol-
erated by these patients. Additionally, according to Polish clinical practice, the patients have to
meet at least one of the following criteria: (1) had an inadequate response to conventional
Fig 1. Structure of Markovmodel for patients with UC.
doi:10.1371/journal.pone.0160444.g001
Table 1. Clinical inputs and utilities used in the model.
Parameter Value 95% LCI 95% UCI Reference
Response rate—6. week Golimumab/standard care (RR) 1.39 1.05 1.84 [7]
Standard care alone 0.24 0.19 0.29 [7]
Remission rate—6. week Golimumab/standard care (RR) 2.79 1.62 4.80 [7]
Standard care alone 0.06 0.04 0.10 [7]
The probability of response per cycle—54. week Standard care alone 0.014 0.008 0.023 [8]
Response per cycle—54. week (RR) Golimumab/standard care 1.46 0.76 2.78 [8]
The probability of remission per cycle—54. week Standard care alone 0.036 0.026 0.050 [8]
Remission per cycle—54. week (RR) Golimumab/standard care 1.53 1.06 2.22 [8]
The probability of response loss per cycle—6–54. week Golimumab/standard care 0.142 - - [8]
Standard care alone 0.161 - - [8]
The probability of remission loss per cycle—6–54. week Golimumab/standard care 0.000 - - [8]
Standard care alone 0.000 - - [8]
The probability of complications after surgery 0.53 0.27 0.53 [10,11]
Surgery rate per cycle Golimumab/standard care (RR) 0.77 0.33 1.86 [9]
Standard care alone 0.75% - - [9]
Utilities Active treatment 0.420 0.320 0.420 [12,13]
Remission 0.880 0.790 0.910 [12,13]
Response 0.760 0.580 0.940 [12]
Remission after surgery 0.610 0.610 0.610 [12]
Complications after surgery 0.420 0.420 0.490 [12,13]
RR—relative risk; LCI—lower confidence interval; UCI—upper confidence interval
doi:10.1371/journal.pone.0160444.t001
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therapies, including corticosteroids and 6-mercaptopurine or azathioprine (the total Mayo
score> 6 points), (2) had failed to tolerate the therapy with corticosteroids and 6-mercaptopu-
rine or azathioprine, (3) had contraindications to the therapy with corticosteroids and 6-mer-
captopurine or azathioprine. The average age of a patient was 40.12 years (95% CI: 38.54–
41.46), and the percentage of women was 46.0% (95% CI: 40.3–51.0%). This was based upon
baseline data from the reference clinical trials the Program of Ulcerative Colitis Research Stud-
ies Utilizing an Investigational Treatment (PURSUIT)—Subcutaneous (SC) [7] and Mainte-
nance (M) [8].
Based on the current practice, registered dosage and reference clinical trials, golimumab was
assumed to be administered in a dose of 200 mg at week 0, 100 mg at week 2, and 50 mg every
four weeks beginning at week 6 up to 1 year [6–8].
Model structure
The modelling was carried out based on a Markov-type cohort simulation process and imple-
mented in Microsoft Excel 2007 with Visual Basic for Applications tool (Microsoft Corpora-
tion, Redmond, WA). The patient enters this model when starting the induction treatment.
The time horizon is divided into 2 periods: from week 0 to 6 (period 1; induction treatment),
and from week 7 to the end of time horizon (period 2; maintenance treatment). The cycle
length during period 1 is 1 week, and cycles in period 2 last 8 weeks. After the seventh cycle,
the response to induction therapy and remission was assessed and biological treatment was
continued only in responders (patients who responded or experienced remission). Mayo score
was used to assess the UC activity (scores can range from 0 to 12, with higher scores indicating
more severe disease activity): values from 0 to 2 means remission, 3–5 mild disease, 6–12 mod-
erate-severe disease [7]. The clinical response was defined as a decrease from the baseline in
the total Mayo score by at least 3 points and at least 30 percent, accompanied by either a rectal
bleeding subscore of 0 or 1 or a decrease from baseline in rectal bleeding by at least 1. Clinical
remission was defined as a Mayo score of 2 points or lower, with no individual subscore
exceeding 1 point [7,8]. In accordance with Polish clinical practice, for standard care, it is
Table 2. Cost inputs used in the model.
Parameter Mean 95% LCI 95% UCI Reference
Drug cost [PLN] Golimumab 1 mg 77.63 - - decree of the Minister of Health
Azathioprine 1 mg 0.0107 - -
Prednisolone 1 mg 0.1055 - -
Mesalazine 1 mg 0.0015 - -
Mercaptopurine 1 mg 0.0166 - -
Monitoring costs per cycle [PLN] 8 weeks cycle 121.56 - - Expert opinion, decree of the President of NHF
1 week cycle 15.20 - -
Administration costs [PLN] 468.00 - - Expert opinion, decree of the President of NHF
Surgery cost [PLN] 12,480 6,240 37,440 Expert opinion, decree of the President of NHF
Complication after surgery treatment [PLN] 4,160 - - Expert opinion, decree of the President of NHF
Standard treatment per cycle [PLN] 8 weeks cycle 204.32 - - decree of the Minister of Health; expert opinion
1 week cycle 25.54 - -
Indirect costs [PLN/year] Remission 6,523.75 - - S1 File
Active disease 22,934.58 - -
PLN—Polish zloty, €1 = 4.2 PLN, based on the average exchange course from the year 2015; NHF—National Health Fund
doi:10.1371/journal.pone.0160444.t002
Golimumab/Standard Care versus Standard Care Alone in UC: Cost-Effectiveness Analysis
PLOS ONE | DOI:10.1371/journal.pone.0160444 August 5, 2016 4 / 11
assumed that in both the induction and maintenance phases, 100% of patients have corticoste-
roids and aminosalicylates, 80% have mercaptopurine, and 20% have azathioprine.
Patients who have neither remission nor response to induction treatment with the TNFα-
inhibitor/standard care or standard care alone will stop the treatment, move to an active dis-
ease state and start standard care alone or will have a colectomy. If one of the treatments (goli-
mumab/standard care or standard care alone) led to a clinical response or remission, the
patient continued with the treatment in the maintenance phase.
Maintenance treatment with golimumab is restricted to 1 year in base-case analysis and no
limitation for biological treatment was assumed in sensitivity analysis (golimumab adminis-
tered until loss of response or death, according to what occurs first). Patients who experienced
the response or remission can sustain or lose it during the next cycle. The treatment can be dis-
continued when unacceptable adverse events occur; in this case the patient moves to a standard
care alone state. Patients who failed golimumab/standard care or standard care alone treatment
continued standard care in the maintenance phase, but they could have a colectomy if their dis-
ease remained active. Standard care is continued regardless of whether the patient has remis-
sion, response or is in an active disease state. All patients who had a colectomy can experience
temporary complications and finally achieve clinical remission after surgery (see: Fig 1). It was
assumed that all complications occur immediately after surgery (in the same cycle) and are
resolved during the 8-week period.
Certain adverse events were not included in the model. In accordance with reference clinical
trials [7,8] the incidences of adverse events and serious adverse events, including serious infec-
tions, were similar for golimumab- and placebo-treated patients. No data was found on the sig-
nificant impact of particular adverse events on the quality of life or costs.
There is no evidence, that patients with UC have lower life expectancy, thus the probability
of death was calculated on a basis of life expectancy table for general Polish population (www.
stat.gov.pl). It was assumed that the probability of death will be the same for each clinical states.
No data was found on the different probability of death from particular clinical states of model
for natural course of the disease.
Clinical inputs
Transition probabilities in the model were calculated based on the response, remission rates
and discontinuation due to adverse event rates which came from randomized, double-blind,
placebo-controlled trials. The PURSUIT-SC and PURSUIT-M studies evaluated the efficacy of
golimumab induction and maintenance therapy of patients with moderate to severe ulcerative
colitis despite conventional treatment [7,8]. As the definitions of remission and response were
overlapping in PURSUIT studies [7,8] responders from this analysis excluded those who
achieved remission. The above provides the separation of these two states in a model.
In PURSUIT-SC study, the effectiveness was assessed at week 6 (after induction treatment)
[7], while in PURSUIT-M study the assessment was made at week 30 and at week 54 (mainte-
nance treatment; data available only for week 54 [8]). Transition probabilities for golimumab/
standard care after discontinuation of the biological treatment were assumed to be the same as
for the standard care alone arm. Clinical parameters and utility values used in the model are
presented in Table 1.
To derive the probability of colectomy, we used data from study by Feagan et al. [9] for ada-
limumab, as no data concerned the colectomy rate after golimumab treatment was identified.
It was estimated that during the 52-week period 3.68% (15 per 408.1 patient-years) and 4.75%
(11 per 231.7 patient-years) of patients treated with adalimumab/standard care and standard
care alone have a colectomy, respectively. Using the above data as our basis we calculated the
Golimumab/Standard Care versus Standard Care Alone in UC: Cost-Effectiveness Analysis
PLOS ONE | DOI:10.1371/journal.pone.0160444 August 5, 2016 5 / 11
probability of a colectomy in one cycle (Table 1), assuming that results for golimumab/stan-
dard care are the same as for adalimumab/standard care.
The probability of surgery complications was calculated based on the study by Arai et al.
[10] and Fazio et al. [11] (Table 1). After resolving the complications within the 8-week period,
it was assumed that patients achieve post-surgical remission, just as patients who didn't experi-
ence any complications.
Costs
The costs were presented in 2016 Polish zloty (PLN) and the results were presented in both
PLN and Euros (€; €1 = 4.2 PLN). Direct medical costs considered in the model included those
related to initiation and maintenance treatment with golimumab (drug and administration
costs), standard care, monitoring and hospitalization cost, surgery costs, and treatment of com-
plications after surgery costs.
The costs of drugs used in the study population are based on the actual unit prices of reim-
bursement medical products. Table 2 presents all drugs' unit costs. The dosage of drugs used in
standard care, as well as monitoring costs were determined by expert opinion.
Indirect costs come from study carried out in Poland on 202 patients with UC (S1 File).
They include absenteeism, presenteeism and costs of leaving earlier the labor market, sepa-
rately for remitted patients and those with active disease. Indirect costs generated by patients
in remission were assigned to responders (patients with respond or remission) and indirect
costs generated by patients with active disease were assigned to the rest.
Utilities and quality of life
A systematic review was made to identify the utility values for different health states in the
model. After analysis of the available data we chose the values presented by Woehl et al. [12]
because this study is the most useful for source utility values of different stages included in the
model, it reported EQ-5D utility values and was carried out on 18,573 patients from United
Kingdom (Table 1). The utility values were reported for following states: remitting disease,
mild disease, and moderate to severe disease. These categories of disease severity were based on
the Simple Colitis Activity Index. We assumed that the utility value for moderate to severe dis-
ease that responded to treatment was equal to the value for mildly active disease by Woehl
et al. [12]. In patients during the treatment or who are in an active disease state or had compli-
cations after surgery, the utility value was assumed to be as in active moderate to severe disease.
We assumed that in the post-surgery remission state the utility value would be lower than in
remission after the treatment state, which reflects the effect of chronic complications after a
colectomy on the patient's quality of life. All utility values are presented in Table 1.
An alternative set of utility values was used in the sensitivity analyses, based on the study by
Arseneau et al. [13]. There was no change in the sensitivity analyses in utility value for remis-
sion after surgery state, to all other states different utility values were assigned and are pre-
sented in Table 1.
Economic analysis
The primary outcome of this simulation study was the ICUR of the treatment with golimu-
mab/standard care and the standard care alone, expressed as an incremental cost per QALY
saved. The ICUR was calculated as the difference in total costs from the public payer's perspec-
tive (only direct costs included) and social perspective (direct and indirect costs included)
divided by the difference in effectiveness in QALYs.
Golimumab/Standard Care versus Standard Care Alone in UC: Cost-Effectiveness Analysis
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Sensitivity analysis
Sensitivity analyses to evaluate the robustness of our findings were conducted. Variability of
cost-effectiveness results according to the change of key variables was assessed using one-way
sensitivity analysis. Values used in sensitivity analysis for clinical, cost and utility parameters
are presented in Tables 1. and 2. Additionally, within the sensitivity analysis, we assumed no
limitation of golimumab treatment (biologic therapy until disease progression, i.e. lose of
response, or death) and higher maintenance dose of golimumab—100 mg.
Parameter uncertainty was evaluated using probabilistic sensitivity analysis (PSA). We used
normal (for cost and clinical parameters), log-normal (for clinical parameters), and beta (for
utility weights) distributions.
Results
Base-case analysis
The results of the base-case analysis are presented in Table 3. The treatment of UC patients
with golimumab/standard care instead of the standard care alone resulted in 0.122 additional
years of life in full health.
The treatment with golimumab/standard care was found to be more expensive than treat-
ment with the standard care alone from the NHF perspective by 47,819 PLN (€11,386) and
from the social perspective by 45,757 PLN (€10,894). The incremental cost per QALY gained
was 391,252 PLN (€93,155) from NHF perspective and 374,377 PLN (€89,137) from social per-
spective (Table 3.).
Sensitivity analysis
Results of various one-way sensitivity analyses are presented in Table 4. The range of ICUR val-
ues obtained during the one-way sensitivity analysis was from 211,990 PLN/QALYG (50,474
€/QALYG) to 959,633 PLN/QALYG (228,484 €/QALYG) from NHF perspective and from
194,071 PLN/QALYG (46,207 €/QALYG) to 946,069 PLN/QALYG (225,255 €/QALYG) from
social perspective. The high influence on the analysis results has a change of remission rates
after induction treatment (week 6) and relative risk of surgery rate (upper value). We also
observed that change of utility value for remission state significantly affected the results. Bio-
logical treatment with no time restriction (until disease progression, i.e. lose of response, or
death) resulted in ICUR value equals 701,517 PLN/QALYG (167,028 €/QALYG) from NHF
perspective and 697,798 PLN/QALYG (166,142 €/QALYG) from social perspective. The differ-
ence in QALY between golimumab/standard care and standard care alone was 0,255 with
Table 3. Base-case results.
End point Golimumab + standard care Standard care alone Incremental value
QALY 19.241 19.118 0.122
Total direct costs—public payer perspective^ 93,321 PLN 45,502 PLN 47,819 PLN
Total direct and indirect costs—social perspective^^ 302,848 PLN 257,092 PLN 45,757 PLN
ICUR—public payer perspective 391,252 PLN/QALYG
ICUR—social perspective 374,377 PLN/QALYG
^ total direct costs include: pharmacotherapy costs (biological treatment), standard care costs, monitoring costs, golimumab administration costs, colectomy
and complications after surgery costs
^^ total indirect costs included absenteeism, presenteeism, cost of early leaving the labor market.
PLN—Polish zloty, €1 = 4.2 PLN, based on the average exchange course from the year 2015
doi:10.1371/journal.pone.0160444.t003
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assumption of no limitation of biological treatment. Assuming the maintenance dose of goli-
mumab equals 100 mg, the ICUR value was 586,586 PLN/QALYG (139,663 €/QALYG) from
NHF perspective and 569,274 PLN/QALYG (135,541 €/QALYG) from social perspective.
Table 4. Sensitivity analysis results.
Parameter ICUR [PLN/QALYG]
Public payer perspective Social perspective
Time horizon—lower value (10 years) 327,428 298,629
Time horizon—upper value (50 years) 394,061 377,954
Discount rate for outcomes—lower value (0%) 395,960 378,882
Discount rate for outcomes—upper value (5%) 389,761 372,950
Discount rate for costs—lower value (0%) 392,850 379,656
Discount rate for costs—upper value (10%) 389,883 370,234
Response—6. week, golimumab/standard care (RR)—lower value 354,712 339,232
Response—6. week, golimumab/standard care (RR)—upper value 444,816 425,897
Response—6. week, standard care alone—lower value 367,131 350,839
Response—6. week, standard care alone—upper value 419,370 401,817
Remission—6. week, golimumab/standard care (RR)—lower value 959,633 946,069
Remission—6. week, golimumab/standard care (RR)—upper value 211,990 194,071
Remission—6. week, standard care alone—lower value 583,193 567,711
Remission—6. week, standard care alone—upper value 280,549 262,871
Response—54. week, golimumab/standard care (RR)—lower value 391,252 374,377
Response—54. week, golimumab/standard care (RR)—upper value 391,252 374,377
Response—54. week, standard care alone—lower value 392,686 375,807
Response—54. week, standard care alone—upper value 389,159 372,291
Remission—54. week, golimumab/standard care (RR)—lower value 391,252 374,377
Remission—54. week, golimumab/standard care (RR)—upper value 391,252 374,377
Remission—54. week, standard care alone—lower value 305,976 288,676
Remission—54. week, standard care alone—upper value 492,087 475,472
Complications after surgery—lower value 391,523 374,621
Complications after surgery—upper value 391,252 374,377
Utility weight, active treatment—lower value 356,528 341,151
Utility weight, active treatment—upper value 391,252 374,377
Utility weight, remission—lower value 509,035 487,080
Utility weight, remission—upper value 363,237 347,570
Utility weight, remission after surgery—lower value 391,252 374,377
Utility weight, remission after surgery—upper value 391,252 374,377
Utility weight, complications after surgery—lower value 391,252 374,377
Utility weight, complications after surgery—upper value 391,403 374,522
Utility weight, response—lower value 452,879 433,346
Utility weight, response—upper value 344,389 329,535
Maximal treatment duration—lower value (12 months) 391,252 374,377
Maximal treatment duration—upper value (360 months) 701,517 697,798
Surgery rate (RR)—lower value 334,186 321,837
Surgery rate (RR)—upper value 676,080 636,619
PLN—Polish zloty, €1 = 4.2 PLN, based on the average exchange course from the year 2015; RR—relative risk; QALYG—Quality adjusted life years
gained; ICUR—incremental cost-utility ratio.
doi:10.1371/journal.pone.0160444.t004
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The results of the Probabilistic Sensitivity Analyses, testing the whole range of all the uncer-
tain parameters, are presented as a cost-effectiveness acceptability curve (Fig 2). The mean
ICUR and the 95% confidence interval for golimumab/standard care when compared to the
standard care alone was 379,685 PLN/QALYG, 95% CI: 246,281–915,800 (90,401 €/QALYG,
95% CI: 58,638–218,048) from the public payer’s perspective and 362,523 PLN/QALYG, 95%
CI: 230,463–881,184 (86,315 €/QALYG, 95% CI: 54,872–209,806) from social perspective. The
results of the PSA suggest golimumab/standard care to be cost-effective with a WTP equals
about 380,000 PLN/QALYG (~ €90,476).
Discussion
Using a 30 years’ time horizon and the restriction for the duration of TNFα inhibitor therapy
to 1 year, golimumab/standard care treatment turned out to be more effective and more costly
option compared with the standard care alone in Poland. One year biologic treatment provided
an ICUR value of 89,137–93,155 €/QALYG, depending on the perspective.
The present economic model is the first study which assesses the golimumab treatment of UC
in Poland with indirect costs of the disease included. We used data from randomized clinical trials
to assess the effectiveness of biological treatment, as there is no data concerned Polish patients.
Such a model can offer support to the decision makers as long as it reflects real-world conditions.
Even though the present study evaluated the cost-effectiveness of golimumab in the Polish setting,
the results could be easily adopted by the healthcare system in other countries. As the clinical prac-
tice (the length of therapy, dosage, indications and contradictions) is commonly based on clinical
studies, the only difference should be the cost of drugs, medical procedures and hospitalization.
The limitation of our study is that we didn't include mortality due to UC because there is an
evidence which indicates that patients with UC have normal life expectancy, subsequently
meaning that treatment will not influence the survival. Additionally, mortality was not an out-
come in the reference clinical studies. We also didn't include treatment related adverse events,
as they have a relatively small impact on the cost and quality of life. Some assumptions had to
be made concerning the utility values. The utility value for mildly active disease was assigned to
patients who responded to treatment, while in patients who had complications after surgery,
the utility value was assumed to be as that in active moderate to severe disease.
Review of published economic analysis for study subject was performed. We found two
studies for golimumab/standard care compared with standard care alone in UC. Canadian
Agency for Drugs and Technologies in Health (CADTH) published a recommendation for
golimumab in UC [14]. Within this recommendation the results of economic analysis carried
Fig 2. Cost-effectiveness acceptability curve showing the probability that golimumab with standard
care is cost-effective versus standard care alone at a range of different threshold values.
doi:10.1371/journal.pone.0160444.g002
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out by the manufacturer were presented. It was reported that when compared with conven-
tional therapy in 10-years time horizon, golimumab 50 mg and 100 mg were associated with an
ICUR of $41,591 (€37,349) and $42,271 (€37,959), respectively. Agency pointed out the key
limitation of the manufacturer's economic evaluation which was the lack of transparency
regarding its methods and how data were included in the model. Agency made their own
assessment for 1.25 and 2.5 years time horizon and obtained ICUR values of $104,000
(€93,392) and $52,000 (€46,696), respectively. Another identified economic evaluation [15]
was presented in a form of abstract, full text is not available. Thorlund et al [15] conducted the
cost-effectiveness analysis of three anti-TNF-alfa inhibitors (infliximab, adalimumab and goli-
mumab). Markov model was used and the analysis was performed in 10 years time horizon
from the Canadian public payer's perspective, considering direct costs only. The ICUR for goli-
mumab was of approximately $40,000 (about €35,920). Golimumab provides a cost-effective
treatment option for patients who have had an inadequate response to conventional therapy
for moderately to severely active ulcerative colitis. As in the case of previous study, it is hard to
compare our results with above, because only abstract or technology assessment report with
limited information about methodology, assumptions, and inputs is available. Published eco-
nomic analysis showed that golimumab/standard care compared with standard care alone in
UC seems to be an cost-effective treatment option, with ICUR value ranged from €35,920 to
€93,392. It is worth to mention that none of the identified studies included indirect costs.
During the review of published economic analysis for biologic therapies used in UC, we also
found the assessment for infliximab, made by Xie et al [16]. Analysis was carried out for Canada
in 5 years’ time horizon. Authors assumed switching to adalimumab therapy after the failure of
infliximab. The ICUR for the biologic treatment strategy (infliximab and adalimumab after fail-
ure of the first biologic therapy) compared with usual care was about 306,761 USD (2015 prices).
The QALYs for the biologic treatment strategy were 2.178, and for the usual care strategy—2.015
(QALYG = 0.163). The difference in QALYs between the compared treatment options was above
the value obtained in our analysis for golimumab/standard care compared with standard care
alone (0.122), which may indicate the higher additional effect of infliximab compared with stan-
dard care than of golimumab/standard care compared with standard care alone. Above conclu-
sion should be interpreted with caution as the control groups in studies for infliximab and
golimumab, as well as utility values, time horizon and model structure can differ significantly.
Some economic evaluations for adalimumab were also found, but all of them were available
only in a form of abstract where limited information was provided. In this connection it was
not possible to compare the clinical effects with those obtained in our analysis.
Our analysis has shown that despite the clinical advantage of biologics, its use constitutes a
heavy burden for the public payer. The treatment of UC patients with golimumab/standard
care in place of a standard care alone resulted in additional quality adjusted life years but also
additional costs. The biologic therapy remains the only treatment option for moderate to severe
chronic UC patients who failed standard treatment or when it is not tolerated.
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